"Designing Growth Strategies is in our DNA"
A clinical abnormality characterized by persistent albuminuria, reduction in glomerular filtration rate (GFR) and elevated arterial blood pressure leading to the deterioration of proper functioning of kidney in patients with type 1 and type 2 diabetes is termed as diabetic nephropathy. It is the common cause of chronic kidney disease worldwide. There are five stages of diabetic nephropathy. Initially, the person may not experience any symptoms, but at stage 4 or 5 they may experience symptoms like swollen ankles and feet due to water retention, dark urine due to blood in urine, worsening blood pressure control, protein in the urine, nausea, vomiting, and loss of appetite.
The main aim of the prevention and treatment of diabetic nephropathy is to maintain and control blood glucose levels and blood pressure levels. Current treatment of diabetic nephropathy includes medications and dietary changes at the initial stages. Drugs like Angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs) can help lower blood sugar levels and protect kidney functions. Later-stage treatment includes dialysis and kidney transplant.
According to the Centers for Disease Control and Prevention (CDC) in 2019, 15% of the U.S population is estimated to suffer from chronic kidney diseases (CKD). This increasing prevalence of kidney diseases is elevating the focus of pharmaceutical companies towards developing new treatment options against diabetic nephropathy. For instance; LMB763, which is being studied by Novartis AG, is currently in phase-2 clinical trials for the study of safety, tolerability, and efficacy of LMB763 in patients with diabetic nephropathy.
To know how our report can help streamline your business, Speak to Analyst
At present, around 48% of the pipeline candidates for diabetic nephropathy are in the phase-2 clinical stage. Maximum studies for diabetic nephropathy are sponsored by pharmaceutical industries.
The report on ‘Diabetic Nephropathy – Pipeline Review, 2019’ provides a comprehensive overview of the drugs that are in the R&D pipeline by indication or molecule for diabetic nephropathy. The report provides a thorough analysis of the distribution of the pipeline products by clinical trial stage, indication, company, therapy area and details such as clinical trial stage, sponsor, description on every product in the pipeline. Products in the preclinical and clinical stage along with dormant & discontinued pipeline candidates are included in the report. The report also covers additional insights such as epidemiology overview and current market scenario for Diabetic Nephropathy.
The report on ‘Diabetic Nephropathy– Pipeline Review, 2019’, which is built by following a robust research methodology involving primary interviews and desk research, provides a complete overview of the R&D activity and pipeline products to assist companies in developing growth strategies and identifying emerging players.